Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
SpringWorks Therapeutics' chief people officer sells $1.6 million in stock
Daniel Pichl, Chief People Officer at SpringWorks Therapeutics (NASDAQ:SWTX), has recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the SEC, Pichl ...
SpringWorks therapeutics director Daniel Lynch sells $9.53 million in stock
Daniel Lynch, a director at SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and ...
SpringWorks Therapeutics price target raised to $87 from $65 at BofA
BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...
BioWorld15h
Springworks’ Gomekli wins priority FDA nod for NF1 neurofibromas
Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...
Cold Stone Creamery Serving Sweet Franchise Opportunities in Nashville
Cold Stone Creamery®, one of the nation's premier ice cream creameries, revealed today its strategic plans to expand the ...